benjamin ory
benjamin ory
Verified email at
Cited by
Cited by
Circulating tumor cells: a review of non–EpCAM-based approaches for cell enrichment and isolation
MT Gabriel, LR Calleja, A Chalopin, B Ory, D Heymann
Clinical chemistry 62 (4), 571-581, 2016
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice
B Ory, MF Heymann, A Kamijo, F Gouin, D Heymann, F Redini
Cancer: Interdisciplinary International Journal of the American Cancer …, 2005
Sarcoma treatment in the era of molecular medicine
TGP Grünewald, M Alonso, S Avnet, A Banito, S Burdach, F Cidre‐Aranaz, ...
EMBO molecular medicine 12 (11), e11131, 2020
Tumour heterogeneity: the key advantages of single-cell analysis
M Tellez-Gabriel, B Ory, F Lamoureux, MF Heymann, D Heymann
International journal of molecular sciences 17 (12), 2142, 2016
Bisphosphonates: new therapeutic agents for the treatment of bone tumors
D Heymann, B Ory, F Gouin, JR Green, F Rédini
Trends in molecular medicine 10 (7), 337-343, 2004
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma
D Heymann, B Ory, F Blanchard, MF Heymann, P Coipeau, C Charrier, ...
Bone 37 (1), 74-86, 2005
Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle
F Lamoureux, M Baud’huin, L Rodriguez Calleja, C Jacques, M Berreur, ...
Nature communications 5 (1), 3511, 2014
Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma
MR Ramsey, L He, N Forster, B Ory, LW Ellisen
Cancer research 71 (13), 4373-4379, 2011
Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation …
B Ory, F Blanchard, S Battaglia, F Gouin, F Redini, D Heymann
Molecular pharmacology 71 (1), 333-343, 2007
FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma
MR Ramsey, C Wilson, B Ory, SM Rothenberg, W Faquin, AA Mills, ...
The Journal of clinical investigation 123 (8), 3525-3538, 2013
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process
G Moriceau, B Ory, L Mitrofan, C Riganti, F Blanchard, R Brion, C Charrier, ...
Cancer Research 70 (24), 10329-10339, 2010
Identification of genomic differences among peripheral arterial beds in atherosclerotic and healthy arteries
M Steenman, O Espitia, B Maurel, B Guyomarch, MF Heymann, ...
Scientific reports 8 (1), 3940, 2018
A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma
B Ory, MR Ramsey, C Wilson, DD Vadysirisack, N Forster, JW Rocco, ...
The Journal of clinical investigation 121 (2), 809-820, 2011
Mechanisms of resistance to conventional therapies for osteosarcoma
L Marchandet, M Lallier, C Charrier, M Baud’huin, B Ory, F Lamoureux
Cancers 13 (4), 683, 2021
MicroRNA‐17‐5p reduces inflammation and bone erosions in mice with collagen‐induced arthritis and directly targets the JAK/STAT pathway in rheumatoid arthritis fibroblast‐like …
A Najm, FM Masson, P Preuss, S Georges, B Ory, T Quillard, S Sood, ...
Arthritis & Rheumatology 72 (12), 2030-2039, 2020
BYL719, a new α‐specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma
B Gobin, MB Huin, F Lamoureux, B Ory, C Charrier, R Lanel, S Battaglia, ...
International journal of cancer 136 (4), 784-796, 2015
Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme
M Cheray, A Etcheverry, C Jacques, R Pacaud, G Bougras-Cartron, ...
Molecular cancer 19, 1-16, 2020
NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate
B Gobin, S Battaglia, R Lanel, J Chesneau, J Amiaud, F Rédini, B Ory, ...
Cancer letters 344 (2), 291-298, 2014
Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival
F Gouin, B Ory, F Rédini, D Heymann
International journal of cancer 119 (5), 980-984, 2006
Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis
M Baud'Huin, F Lamoureux, C Jacques, LR Calleja, T Quillard, C Charrier, ...
Bone 94, 10-21, 2017
The system can't perform the operation now. Try again later.
Articles 1–20